Blosozumab

Blosozumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	SOST
Clinical data
ATC code	none
Identifiers
CAS Number	1132758-87-2^N
ChemSpider	none
UNII	83YOM0NEL5
KEGG	D10094^N
Chemical and physical data
Formula	C₆₄₆₂H₉₈₅₂N₁₆₈₄O₂₀₃₀S₄₆
Molar mass	145086.42 g·mol⁻¹
^NY (what is this?) (verify)

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.^[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.^[2]

Blosozumab was developed by Eli Lilly and Company.

References

^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).^{[dead link]}
^ McColm J, Hu L, Womack T, Tang CC, Chiang AY (April 2014). "Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women". Journal of Bone and Mineral Research. 29 (4): 935–43. doi:10.1002/jbmr.2092. PMID 23996473.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Musculoskeletal

Human	Stamulumab^†

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab^† Lecanemab Erenumab Fasinumab^† Fulranumab Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab^†

Angiogenesis inhibitor

Humanized	Ranibizumab

Growth factor

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

This page was last edited on 20 December 2023, at 19:30

From Wikipedia, the free encyclopedia

References